- Adults (18-64 years)
- People at high risk of STIs
- Men who have sex with men
- Outpatient clinic
- Non-hospital health centre
- STD/STI clinic
- Monkeypox virus
- Mpox
Setting: Non-hospital health centre
Healthcare facilities outside hospitals, such as long term care facilities, community health centers, and vaccination centers
- Adults (18-64 years)
- People at high risk of STIs
- Outpatient clinic
- Non-hospital health centre
- STD/STI clinic
- Monkeypox virus
- Mpox
- Adults (18-64 years)
- General population
- Non-hospital health centre
- Vaccination centre
- Monkeypox virus
- Mpox
- Pharmacological intervention
- Vaccination
- Adults (18-64 years)
- General population
- Non-hospital health centre
- Vaccination centre
- Monkeypox virus
- Mpox
- Pharmacological intervention
- Vaccination
- Adults (18-64 years)
- General population
- Hospital
- Non-hospital health centre
- Vaccination centre
- Monkeypox virus
- Mpox
- Blood sample
- Pharmacological intervention
- Vaccination
- MVA-BN
- Adults (18-64 years)
- Fragile population
- People at high risk of STIs
- Immunocompromised host
- PrEP users
- People living with HIV
- Outpatient clinic
- Non-hospital health centre
- STD/STI clinic
- Monkeypox virus
- Mpox
- General population
- Adolescents (12-17 years)
- Non-hospital health centre
- Telemedicine
- SARS-CoV-2
- Post-COVID-19
- Adults (18-64 years)
- General population
- People at high risk of STIs
- Outpatient clinic
- Non-hospital health centre
- STD/STI clinic
- Monkeypox virus
- Mpox
- Adults (18-64 years)
- General population
- Outpatient clinic
- Non-hospital health centre
- STD/STI clinic
- Monkeypox virus
- Mpox
- Adults (18-64 years)
- People at high risk of STIs
- Men who have sex with men
- Hospital
- Outpatient clinic
- Non-hospital health centre
- STD/STI clinic
- Monkeypox virus
- Mpox
- Adults (18-64 years)
- Elderly (≥65 years)
- Fragile population
- Outpatient clinic
- Community
- Non-hospital health centre
- SARS-CoV-2
- Acute COVID-19
- Pharmacological intervention
- Antivirals
- Monoclonal antibodies
- Nirmatrelvir/Ritonavir
- Sotrovimab
- Molnupiravir
- Adults (18-64 years)
- Elderly (≥65 years)
- Fragile population
- Adolescents (12-17 years)
- Immunocompromised host
- Outpatient clinic
- Community
- Non-hospital health centre
- SARS-CoV-2
- Acute COVID-19
- Pharmacological intervention
- Monoclonal antibodies
- Sotrovimab